About
Sai Parenteral’s Limited is a diversified pharmaceutical formulations company incorporated in January 2001. It was originally established as a private limited company and was converted into a public limited company in January 2022. Anil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna promote the Company. The Company operates across branded generic formulations and contract development and manufacturing (CDMO) services. Its product portfolio spans multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, antibiotics, gastroenterology, respiratory care, dermatology, and vitamins and supplements. Offerings cover a wide range of dosage forms such as injectables, tablets, capsules, liquid orals and ointments.
Sai Parenteral has strong capabilities in sterile injectable manufacturing, including dry powder injections, vials, ampoules and pre-filled syringes. Its operations are supported by multiple manufacturing facilities in Telangana and Andhra Pradesh, along with in-house research and development capabilities. The Company follows an integrated business model, combining product development, manufacturing and customer-centric execution. Its key strengths include diversified product offerings, established manufacturing infrastructure, regulatory-focused processes and long-standing promoter-led management experience.
IPO schedule
| Issue open date | 2026-03-24 |
|---|---|
| Issue close date | 2026-03-27 |
| UPI mandate deadline | 2026-03-27 (5 PM) |
| Allotment finalization | 2026-03-30 |
| Refund initiation | 2026-04-01 |
| Share credit | 2026-04-01 |
| Listing date | 2026-04-02 |
| Mandate end date | 2026-04-12 |
| Lock-in end date for anchor investors (50%) | 2026-04-29 |
| Lock-in end date for anchor investors (remaining) | 2026-06-28 |
Financials
| Financial Year Ended | March 2024 | March 2025 | September 2025 |
|---|---|---|---|
| Total Assets | 268.1 | 272.39 | 376.24 |
| Revenue | 155.18 | 163.74 | 89.43 |
| Profit After Tax | 8.42 | 14.43 | 7.76 |
Utilisation of Proceeds
| Purpose | INR crores (%) |
|---|---|
| Capacity expansion and upgradation of manufacturing facilities | 110.8 (38.88%) |
| Establishment of a new R&D Centre | 18.02 (6.32%) |
| Repayment/prepayment of certain outstanding borrowings | 14.3 (5.02%) |
| Working capital requirements | 33 (11.58%) |
| Investment in wholly owned subsidiary (Sai Parenterals Pte Ltd, Singapore) for the acquisition of Noumed Pharmaceuticals Pty Ltd (Australia) | 35.64 (12.51%) |
| General corporate purposes | 73.24 (25.76%) |
Strengths
- Diversified pharma portfolio across branded generics and CDMO services
- Strong capabilities in sterile injectable manufacturing
- Presence across multiple therapeutic areas and dosage forms
- Promoter-led management with a long operating track record
- Multiple manufacturing facilities supported by in-house R&D
Risks
- High revenue dependence on injectable formulations
- Manufacturing facilities are concentrated in limited geographies
- Exposure to stringent regulatory inspections and compliance risks
- Dependence on third-party suppliers for key raw materials
- Customer concentration may affect revenue stability
Allotment Status for Sai Parenteral
To check your IPO allotment status:
- Visit the Bigshare Services IPO Application Status page.
- Select the company name from the dropdown menu.
- Select and enter one of the following: PAN, Application Number, DP/Client ID, or Account Number/IFSC.
- Click Submit to view your allotment status